# Explore Targeted Radiation Therapy

## Breast IORT | Electronic Brachytherapy

INNOVATIVE CANCER SOLUTIONS
CARIBBEAN LIMITED

# Precision therapy. Personalized care.



## For us, it's personal.

We share your passion for targeted cancer care expertly tailered to meet your patients' personalized needs. We designed the Xoft ® Axxent ® Electronic Brachytherapy (eBx®) System to empower physicians with full confidence to precisely and effectively treat cancer and enable their patients to live healthy, high-quality lives.

Xoft offers patients and physicians a simplified alternative to radiation six-week radiation therapy for early stage breast cancer treatment. With the Xoft System, delivery of radiation therapy in the operating room at the time of surgery is possible with intraoperative radiation therapy (IORT). Our commitment to this innovative technology is driven by the unique and valuable benefits if offers to you, your facility and your patients.

**By providing select early-stage breast cancer patients with radiation therapy at the time of lumpectomy, our high dose, low energy IORT treatment eliminates weeks of traditional radiation therapy.**

**This quickly streamlines the delivery of care, increasing patient compliance and satisfaction, as well as positioning both you and your facility as a leader in patient-centric, cutting-edge medicine.**

## Targeted

A miniaturized x-ray source delivers a precise dose of radiation directly to the tumor site, the area with the highest risk of recurrence, immediately following surgery. This carefully destroys cancer cells and spares surrounding healthy tissue.

## Efficient

Weeks of traditional radiation post-lumpectomy present a variety of challenges and stressors for many patients. This may result in patients electing a mastectomy rather than breast-conserving surgery, or failing to comply with followup treatment.

With IORT, radiation therapy can be adapted to the personalized needs of the patient. IORT with the Xoft System is delivered at the time of surgery, offering a simple, 1-day treatment solution and improved quality of life for appropriately selected patients.

## Versatile

IORT may be utilized to deliver a single fraction or boost dose. Early clinical results have shown that IORT as a boost using the Xoft System at the time of surgery is safe with low morbidity, a low rate of side effects, and the majority of patients have had excellent to good cosmetic results.

When used as a boost dose, IORT may allow for reduction of subsequent traditional radiation therapy by approximately one week.

# A life-changing treatment option for her

### Fewer side effects

A proven safe and effective treatment option, IORT results in fewer side effects for patients compared to traditional treatment.[6-8]

### Reduced costs

By streamlining the delivery of radiation therapy, IORT offers a cost-effective solution for both physicians and patients.[3]

100% of patients in a clinical study were very pleased with the Xoft breast IORT treatment experience and outcome on follow up visits.[9]

### Increased convenience

IORT offers a simplified approach to radiation treatment for early-stage breast cancer in 1 day, eliminating weeks of EBRT.

### Improved quality of life

A targeted, personalized, shortened overall regimen, IORT allows patients to return to their normal lives sooner and achieve increased quality of life.

www.incansol.com

# Explore a revolutionary treatment option offering promising results

A growing body of favorable clinical data supports the use of IORT in patients meeting specific selection criteria.

## Study verifies effectiveness of IORT

The results of the randomized, multi-national TARGIT-A clinical trial of 3,451 patients at 33 centers concluded that IORT is non-inferior to EBRT. The study establishes that IORT concurrent with lumpectomy within a risk-adapted approach should be considered as an option for eligible patients with breast cancer carefully selected as per the TARGIT-A trial protocol, as an alternative to postoperative EBRT.[6]

## ExBRT clinical trial evaluates safety & efficacy of IORT

***"A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent eBx System at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer"***

Xoft is completing enrollment for the largest clinical trial to-date of IORT using the Xoft System. The prospective, multi-center study compares IORT with the Xoft System to traditional EBRT in 1,200 patients in 27 centers. Early results have demonstrated low rates of recurrences and high-grade adverse events with excellent to good cosmesis two years post-treatment with IORT.[5]

## Research from Hoag Memorial Hospital Presbyterian

Physicians at the Hoag Breast Center in Newport Beach, CA are conducting extensive research on IORT for early-stage breast cancer using the Xoft System. Preliminary results have shown that x-ray based IORT is a promising treatment modality with relatively few complications that greatly simplifies the delivery of post-excision radiation therapy in patients diagnosed with early-stage breast cancer.[7,8]

The Hoag Memorial Hospital Presbyterian IORT series is currently the largest single-facility IORT series with the Xoft System in the United States.



*"Early results from the ExBRT study suggest that IORT is a safe and effective treatment option offering valuable benefits to patients who meet specific selection criteria. I am very encouraged by these results as IORT may also improve patient quality of life by greatly reducing the number of treatments patients receive when compared to EBRT."*

– Alam M. Nisar Syed, MD
Co-Principal Investigator, ExBRT study
Medical Director, Radiation Oncology & Endocurietherapy
MemorialCare Cancer Institute,
Long Beach Memorial Medical Center

# Driving excellence in patient-centric, value-based care

> *My passion has been to trim the treatment to fit the patient, and that's what this is all about. I think IORT is the future of early-stage breast cancer treatment, and we are pleased to offer this one-day solution enabling patients to better maintain their quality of life.*

– Barb Schwartzberg, MD, FACS
Breast Surgeon
Sarah Cannon/HealthONE,
Rose Medical Center

## Rose Medical Center

For more than 60 years, Rose Medical Center (RMC) has provided leading-edge healthcare services to more than 160,000 patients annually in the Denver, CO community. RMC has been frequently recognized for outstanding clinical outcomes and patient safety.

Seeking to strengthen their distinguished reputation as a front-runner in cancer treatment, the 422-bed facility was searching for an innovative breast cancer treatment solution to increase patient awareness and surpass standards of care. In 2011, RMC became the first hospital to adopt electronic brachytherapy with the Xoft System in Denver.

Offering IORT enabled the facility to attract new patients and drive demand, generating a 16% increase in breast surgeries from 2011 to 2012 and a 20% increase in outpatient throughput. Additionally, radiation treatments increased by 1.5% and unique patients grew by 14%. New patients who did not qualify for IORT still chose to receive EBRT at RMC, resulting in a steady increase in EBRT and other services since implementing IORT.

By expanding their comprehensive breast care program with IORT, RMC's adoption of the Xoft System has catalyzed revolutionary growth for the facility while improving patient care.

## Parkridge Medical Center

Parkridge Medical Center (PMC) has served the Chattanooga, TN community for nearly 40 years and has earned recognition as a trusted healthcare leader for its use of advanced technology and its commitment to compassionate and high-quality patient care.

In a highly competitive market environment, the 275-bed medical center sought an innovative, cost-effective treatment solution to expand its portfolio of radiation oncology services. In 2010, PMC became the first hospital to offer electronic brachytherapy with the Xoft System in Tennessee.

The hospital's adoption of the Xoft System elevated public perception and interest in the facility, driving a 35% increase in breast consults and a 20% increase in patients receiving other services. Approximately 20% of the hospital's breast consults result from breast IORT referrals.

PMC's adoption of the Xoft System has enabled the facility to increase referrals, attract new patients, and capitalize on ancillary services while enhancing its comprehensive ancer care program.

# Exceptional clinical innovation at your fingertips

Our passion for targeted cancer care starts at the source.

Our proprietary, miniaturized x-ray source is isotope-free and operates at 50 kV to deliver high dose rate, low energy radiation. The source is placed inside the applicator and energized to deliver a precise, prescribed dose of radiation.

Our versatile Xoft System utilizes electronic brachytherapy to provide expanded treatment options for a range of cancers. The Xoft System is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer, and gynecological cancers. Indications currently under investigation include prostate, pancreatic, colorectal and brain cancers.

## Axxent Accessories



Axxent Balloon Applicators



Axxent FlexiShield



Axxent Rigid Shield




Flexible arm facilitates precise positioning

Touch screen panel offers easy-to-read, step-by-step instructions and real-time treatment information

Bar code scanner streamlines accurate data entry

USB connector communicates individualized treatment plan

Fast dose fall-off enables treatment in a standard operating room with minimal shielding requirements

Weighing approximately 200 pounds with a small footprint, the Xoft System is highly mobile and portable

Xoft®
a subsidiary of iCAD®


# A trusted partner for lasting success

Our commitment to delivering quality patient care spans beyond our state-of-the-art technology. In addition to innovative, personalized treatment options, Xoft is pleased to offer you and your team expert training and support.

## Training & Clinical Support

Comprehensive product training including clinical best practices offers valuable guidance to you and your team.

## Global User Network

Access a virtual, multi-disciplinary network of global providers sharing their clinical experience with Xoft IORT.

## Marketing

Our Marketing Assistance Program (**MAP**) is designed to help you establish and grow your breast IORT practice. Through MAP, you will benefit from a complete package of customizable marketing materials and educational resources developed to support breast IORT at your facility.

## Reimbursement Support Services

Our dedicated team of reimbursement experts can provide answers to questions related to coding, billing and claims.

References: 1. Dickler, A et al. A dosimetric comparison of MammoSite high-dose-rate brachytherapy and Xoft Axxent electronic brachytherapy. Brachytherapy 2007, Volume 6, Issue 2, 164 – 168. 2. William F. Athas, et al. New Mexico Tumor Registry, University of New Mexico Health Sciences Center, Albuquerque. Travel Distance to Radiation Therapy and Receipt of Radiotherapy Following Breast-Conserving Surgery. Journal of the National Cancer Institute, Vol. 92, No. 3, February 2, 2000. 3. Vaidya A, et al. PCN148 Cost Effectiveness Analysis of Targeted Intraoperative Radiotherapy Alone (TARGIT-A) in Early Breast Cancer Patients: Value In Health 17 (2014) A323–A686. TARGIT-A Trial performed with Carl Zeiss Meditec AG Intrabeam System. 4. Syed N, et al. Multicenter Trial of Intra-operative Electronic Brachytherapy During Breast Conservation Surgery for Early Stage Breast Cancer: Early Results of Unplanned Boost Participants. Presented at San Antonio Breast Cancer Symposium 2016. 5. Syed N, et al. Two-year Follow-up Results of a Multi-center Trial of Intra-operative Electronic Brachytherapy During Breast Conservation Surgery for Early Stage Breast Cancer. Presented at San Antonio Breast Cancer Symposium 2016. 6. Vaidya A, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. The Lancet. Volume 383, No. 9917, p603–613, 15 February 2014. TARGIT-A Trial performed with Carl Zeiss Meditec AG Intrabeam System. 7. Epstein M, et al. Acute and Chronic Complications in Breast Cancer Patients Treated with Intraoperative Radiation Therapy. Ann Surg Oncol. 2016 Oct;23(10):3304-9. 8. M Silverstein, et al Intraoperative Radiation Using Low-Kilovoltage X-Rays for Early Breast Cancer: A Single Site Trial. The Annals of Surgical Oncology; August 2017 Online. 9. Proulx G. Intraoperative Radiation (IORT) as Adjuvant Radiation Monotherapy for Early-Stage Breast Cancer Patients Treated with Breast Conserving Surgery. Presented at the American Brachytherapy Society Annual Meeting 2017.

Mc463 Rev A

INNOVATIVE CANCER SOLUTIONS
CARIBBEAN LIMITED

Innovative Cancer Solutions Caribbean Limited
Tel: 868.280.4678 (IORT)
www.incalsol.com
contact@incansol.com
/incansol

# Notes

INNOVATIVE CANCER SOLUTIONS
CARIBBEAN LIMITED

Innovative Cancer Solutions Caribbean Limited
Tel: 868.280.4678 (IORT)
www.incalsol.com
contact@incansol.com
/incansol

# Notes

INNOVATIVE CANCER SOLUTIONS
CARIBBEAN LIMITED

Innovative Cancer Solutions Caribbean Limited
Tel: 868.280.4678 (IORT)
www.incalsol.com
contact@incansol.com
/incansol

# Notes

INNOVATIVE CANCER SOLUTIONS
CARIBBEAN LIMITED

Xoft®
a subsidiary of iCAD®

## For more information visit

868.280.4678 (IORT) /incansol contact@incansol.com

# www.incansol.com